Medpace Logo

For Immediate Release: May 7, 2018

Julie Hopkins
513-579-9911 x 12627

Medpace Announces Increased Sponsorship in the 2018 Hyde Park Blast

CINCINNATI, OH — (May 7, 2018) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that it will increase its sponsorship in the Hyde Park Blast, an annual fundraising event that takes place in the Hyde Park community every summer. The 2018 Hyde Park Blast will occur on June 30 and features a full day of activities, including a 4-mile run, kids’ runs, bike races, chariot races and a block party on Hyde Park Square. It serves as a great way for the community to have fun, be active and raise money for two Cincinnati based cancer-fighting charities: The Cure Starts Now and the Karen Wellington Foundation.

“We have been a local sponsor of the Hyde Park Blast for a number of years,” commented Stephen Ewald, General Counsel & Corporate Secretary at Medpace. “Being part of this event in our local community that helps fund cancer research is completely in line with our mission of accelerating the global development of safe and effective medical therapeutics.

In addition to having a booth, Medpace will also be sponsoring a portion of the race. The “Medpace Final Mile” will be the last mile of the 4-mile course, a scenic and challenging loop around the Hyde Park neighborhood. Awards will be given to the fastest male and female runners in each of the six age groups. Medpace will be sharing ongoing updates regarding its involvement in the 2018 Hyde Park Blast via its social media accounts. Follow Medpace on Facebook and LinkedIn for additional announcements.

Registration for the 17th annual Hyde Park Blast is now open. Learn more about the events and sign up today.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,600 people across 35 countries.